CX3CL1 and obesity disorder: Inhibition of hypothalamic fractalkine (CX3CL1) reduces diet-induced hypothalamic inflammation and recruitment of BM monocytic cells to the hypothalamus, reduces obesity, and protects against glucose intolerance [123].